文献速递中医内科中药与中成药合理使用

补肺益肾方通过抑制p65、JNK和p38改善COPD炎症

A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38.
PubMed 文献 · Phytomedicine · 2021-01-20

补肺益肾方(BYF)是治疗慢性阻塞性肺疾病(COPD)的中药复方。一项四中心开放标签随机对照试验的亚组分析显示,BYF联合常规西药可减少COPD急性加重频率和持续时间、改善呼吸困难评分和6分钟步行距离,但不改变肺功能指标。动物和细胞实验表明,BYF关键活性分子通过抑制NF-κB p65、JNK和p38信号通路发挥抗炎作用。

要点

  • BYF联合常规西药可减少COPD急性加重频率(p<0.001)和持续时间(p=0.028)。
  • BYF可改善呼吸困难评分(p=0.007)和6分钟步行距离(p=0.048),但不改善FEV1等肺功能指标。
  • BYF关键活性分子通过抑制p65、JNK和p38通路减轻COPD炎症。

核心结论

  • 补肺益肾方通过抑制炎症反应改善COPD患者的急性加重频率、持续时间和运动能力,其机制与下调p65、JNK和p38信号通路有关。

研究设计与样本

  • 研究纳入134例完成研究的COPD患者,其中试验组68例接受BYF联合常规西药,对照组66例接受常规西药;数据来自四中心开放标签随机对照试验的亚组分析。
  • 动物实验采用COPD大鼠模型,给予BYF关键活性分子治疗8周;体外实验采用COPD细胞模型给予关键活性分子干预。

主要发现

  • BYF治疗组患者COPD急性加重频率降低(p<0.001),急性加重持续时间缩短(p=0.028),呼吸困难评分改善(p=0.007),6分钟步行距离增加(p=0.048)。
  • BYF治疗组与对照组在用力肺活量(FVC)、第一秒用力呼气容积(FEV1)及FEV1占预计值百分比方面无差异。
  • BYF关键活性分子改善COPD大鼠的肺功能(包括潮气量、每分通气量、呼气峰流速、FVC、FEV0.1和FEV0.3)及病理改变。
  • BYF关键活性分子显著降低COPD大鼠血清和支气管肺泡灌洗液中白介素6(IL6)、肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶9(MMP9)和MMP12水平。
  • BYF关键活性分子降低气道上皮细胞中TNF-α诱导的IL8和IL6水平,其抗炎作用通过抑制NF-κB p65、JNK和p38信号通路介导。

关键数值与推荐

  • BYF治疗组相比对照组,急性加重频率p<0.001,持续时间p=0.028,呼吸困难评分p=0.007,6分钟步行距离p=0.048。
  • FVC、FEV1及FEV1%预计值在两组间无差异。

临床怎么用

  • 对于COPD患者,可考虑在常规西药治疗基础上联合补肺益肾方,以减少急性加重频率和持续时间、改善呼吸困难和运动耐量。
  • 补肺益肾方对肺功能指标(FEV1等)无明显改善作用,临床应结合患者具体情况个体化使用。

局限性

  • 本研究为四中心开放标签随机对照试验的亚组分析,样本量有限(完成研究134例),结果需进一步验证。
  • 动物实验和体外实验的结果不能直接等同于临床疗效,机制结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bufei Yishen formula (BYF), a traditional Chinese medicine (TCM), is an effective therapeutic strategy for patients with chronic obstructive pulmonary disease (COPD). PURPOSE: To evaluate the efficacy of BYF and investigate its therapeutic mechanisms. METHODS: A total of 134 patients completed the study: 68 patients treated by BYF combined with conventional Western medicine in the trial group; and 66 patients treated using conventional Western medicine in the control group. The efficacy of BYF was evaluated by a subgroup analysis of data obtained from a four-center, open-label, randomized controlled trial of comprehensive TCM interventions. A rat model of COPD was treated with the key active molecules (KAM) of BYF for 8 weeks. An in vitro model of COPD was also treated with KAM. RESULTS: Patients treated with BYF had reduced frequency of acute exacerbation of COPD (p < 0.001) and duration (p = 0.028), dyspnea scale (p = 0.007), 6-min walking distance (p = 0.048). There were no differences observed in forced vital capacity in one second (FVC), forced expiratory volume in one second (FEV1), and FEV1 percentage of the predicted value (FEV1%). The five KAM of BYF (KAM-BYF) improved lung function, including tidal volume, minute ventilation, peak expiratory flow, FVC, FEV0.1, and FEV0.3, and pathological changes in COPD rats. Treatment with KAM-BYF markedly decreased the levels of interleukin 6 (IL6), tumor necrosis factor-α (TNF-α), matrix metalloproteinase 9 (MMP9), and MMP12 in serum and bronchial alveolar lavage fluid. In airway epithelial cells, KAM-BYF decreased the levels of TNF-α-induced IL8 and IL6. Finally, we discovered that the anti-inflammatory effects of KAM-BYF in COPD rats and BEAS-2Bs were mediated through inhibition of nuclear factor-kappaB (NF-κB) p65, c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase signaling. CONCLUSIONS: BYF exerts beneficial effects in patients with COPD via inhibition of inflammation.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Li J, Xie Y, Zhao P, et al. A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38. Phytomedicine. 2021. PMID: 33545548. doi:10.1016/j.phymed.2021.153475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。